# reload+after+2024-01-20 08:47:45.168879
address1§400 Alexander Park
city§Princeton
state§NJ
zip§08540
country§United States
phone§646 768 9780
website§https://www.urogen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
fullTimeEmployees§192
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Elizabeth A. Barrett', 'age': 61, 'title': 'President, CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 1117365, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dong  Kim', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 546685, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason Drew Smith', 'age': 51, 'title': 'General Counsel, Chief Compliance Officer & Corporate Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 717582, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Vincent I. Perrone', 'title': 'Senior Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bryon  Wornson', 'title': 'Executive Vice President of Talent, Advocacy & Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sari  Prutchi-Sagiv Ph.D.', 'title': 'Marketing Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marina  Konorty', 'title': 'Executive Vice President of Research & Development and Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark P. Schoenberg M.D.', 'age': 65, 'title': 'Chief Medical Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 579505, 'exercisedValue': 0, 'unexercisedValue': 584496}, {'maxAge': 1, 'name': 'Mr. Jeffrey  Bova M.B.A.', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Ottinger R.ph.', 'title': 'Executive Vice President of Regulatory Affairs & Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§2
compensationRisk§8
shareHolderRightsRisk§1
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.009
priceToSalesTrailing12Months§5.5161905
currency§USD
dateShortInterest§1702598400
forwardEps§-2.59
exchange§NGM
quoteType§EQUITY
shortName§UroGen Pharma Ltd.
longName§UroGen Pharma Ltd.
firstTradeDateEpochUtc§1493904600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§5e073096-dd64-3395-84b4-3b44201f1a30
gmtOffSetMilliseconds§-18000000
targetHighPrice§54.0
targetLowPrice§18.0
targetMeanPrice§39.0
targetMedianPrice§42.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§6.215
grossMargins§0.87916
ebitdaMargins§-0.91053003
trailingPegRatio§None
